The effects of pituitary adenylate cyclase activating polypeptide in renal ischemia/reperfusion

Acta Biol Hung. 2014 Dec;65(4):369-78. doi: 10.1556/ABiol.65.2014.4.1.

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP ) is a multifunctional neuropeptide occurring in the nervous system as well as in the peripheral organs. Beneficial action of PACAP has been shown in different pathological processes. The strong protective effects of the peptide are probably due to its complex modulatory actions in antiapoptotic, anti-inflammatory and antioxidant pathways. In the kidney, PACAP is protective in models of diabetic nephropathy, myeloma kidney injury, cisplatin-, gentamycin- and cyclosporin-induced damages. Numerous studies have been published describing the protective effect of this peptide in renal ischemia/reperfusion. The present review focuses on the ischemia/reperfusion-induced kidney injury and gives a brief summary about the results published in this area.

Keywords: Kidney; PACAP; ischemia/reperfusion; renoprotection.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Humans
  • Kidney / enzymology*
  • Kidney Diseases / enzymology
  • Kidney Diseases / pathology
  • Kidney Diseases / prevention & control*
  • Pituitary Adenylate Cyclase-Activating Polypeptide / administration & dosage
  • Pituitary Adenylate Cyclase-Activating Polypeptide / metabolism*
  • Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide / metabolism
  • Reperfusion Injury / enzymology*
  • Reperfusion Injury / pathology
  • Signal Transduction

Substances

  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide